NCI-H322 has been used to study the preclinical antitumor efficacy of BAY 1129980, which is an anti-C4.4A (Ly6/PLAUR domain-containing protein 3 precursor-LYPD3) antibody–drug conjugate for the treatment of non–small cell lung cancer.

Test system for evaluating cytotoxicity and genotoxicity of chemicals to human lung

Human Caucasian bronchioalveolar carcinoma

NCI-H322 was derived in 1981 from a primary bronchioalveolar carcinoma of the lung from a 52 year old male taken prior to treatment. Ultrastructural studies of this non-small cell carcinoma cell line demonstrated the presence of cytoplasmic structures characteristic of Clara cells. NCI-H322 do not express UDP-glucuronosyltransferase, but are reported to express glutathione-S-transferase and phenol sulfotransferase. Expression of protein and RNA of SP-A, the major surfactant-associated protein was detected. The cells produce tumours in athymic mice.

RPMI 1640 + 2mM Glutamine + 5-10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 1-3x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.